Transcription Factor DP1
-
Subject Areas on Research
- A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-cyclin A complex.
- A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
- A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4.
- A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation.
- Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.
- An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
- Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest.
- Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression.
- Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells.
- Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A.
- Cell cycle: Flies teach an old dogma new tricks.
- Collaborative role of E2F transcriptional activity and G1 cyclindependent kinase activity in the induction of S phase.
- Disruption of cell-cycle control by viral oncoproteins.
- Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes.
- E2F4-RB and E2F4-p107 complexes suppress gene expression by transforming growth factor beta through E2F binding sites.
- E2F: a link between the Rb tumor suppressor protein and viral oncoproteins.
- Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
- Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
- Expression of the HsOrc1 gene, a human ORC1 homolog, is regulated by cell proliferation via the E2F transcription factor.
- Functional properties of a Drosophila homolog of the E2F1 gene.
- Identification of distinct roles for separate E1A domains in disruption of E2F complexes.
- Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function.
- Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
- Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
- Isolation and initial characterization of the BRCA2 promoter.
- Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
- Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F.
- Oncogenic capacity of the E2F1 gene.
- Regulation of the cyclin E gene by transcription factor E2F1.
- Role of the Rb/E2F pathway in cell growth control.
- Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis.
- The E2F transcription factor is a cellular target for the RB protein.
- The Rb-related p107 protein can suppress E2F function independently of binding to cyclin A/cdk2.
- The Rb/E2F pathway and cancer.
- The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state.
- The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter.
- The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F.
- Therapeutic applications of transcription factor decoy oligonucleotides.
- Transcriptional regulation. A closer look at E2F.